Yahoo Finance Today’s Research Reports on Cipher Pharmaceuticals, CRH Medical, ProMIS Neurosciences and Cardiome Pharma
NEW YORK, NY / ACCESSWIRE / February 14, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.
RDI has Initiated Coverage Today on:
Cipher Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=CPH.TO
CRH Medical Corp.
https://rdinvesting.com/news/?ticker=CRH.TO
ProMIS Neurosciences Inc.
https://rdinvesting.com/news/?ticker=PMN.TO
Cardiome Pharma Corp.
https://rdinvesting.com/news/?ticker=COM.TO
Cipher Pharmaceuticals' stock edged 0.98% lower Tuesday, to close the day at $4.06. The stock recorded a trading volume of 3,400 shares, which was below its three months average volume of 12,800 shares. In the last year, Cipher Pharmaceuticals' shares have traded in a range of 3.66 - 5.75. The stock is currently trading 29.39% below its 52 week high. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $4.33 is below its 200-day moving average of $4.68. Shares of Cipher Pharmaceuticals have fallen approximately 17.14 percent year-to-date.
Access RDI's Cipher Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=CPH.TO
On Tuesday, shares of CRH Medical recorded a trading volume of 66,313 shares, which was below the three months average volume of 377,366 shares. The stock ended the day 0.87% lower at 3.42. The share price has gained 83.87% from its 52 week low with a 52 week trading range of 1.86 - 12.35. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $3.47 is greater than its 200-day moving average of $3.08. Shares of CRH Medical are trading at a Price to Earnings ratio of 38.43. Shares of CRH Medical have gained approximately 3.32 percent year-to-date.
Access RDI's CRH Medical Corp. Research Report at:
https://rdinvesting.com/news/?ticker=CRH.TO
ProMIS Neurosciences' stock moved 3.92% higher Tuesday, to close the day at $0.53. The stock recorded a trading volume of 433,218 shares, which was below its three months average volume of 1,129,828 shares. In the last year, ProMIS Neurosciences' shares have traded in a range of 0.14 - 0.73. The share price has gained 278.57% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.37 is greater than its 200-day moving average of $0.27. Shares of ProMIS Neurosciences have gained approximately 165 percent year-to-date.
Access RDI's ProMIS Neurosciences Inc. Research Report at:
https://rdinvesting.com/news/?ticker=PMN.TO
On Tuesday, shares of Cardiome Pharma recorded a trading volume of 3,780 shares, which was below the three months average volume of 17,615 shares. The stock ended the day 2.17% lower at 1.80. The stock is currently trading 70.30% below its 52 week high with a 52 week trading range of 1.64 - 6.06. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $1.91 is below its 200-day moving average of $2.52. Shares of Cardiome Pharma have fallen approximately 5.76 percent year-to-date.
Access RDI's Cardiome Pharma Corp. Research Report at:
https://rdinvesting.com/news/?ticker=COM.TO
Our Actionable Research on Cipher Pharmaceuticals Inc. (TSX:CPH.TO), CRH Medical Corp. (TSX:CRH.TO), ProMIS Neurosciences Inc. (TSX:PMN.TO) and Cardiome Pharma Corp. (TSX:COM.TO) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
